U.S. must develop plan to protect clinical trials as national security asset
Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and generate soft power through health diplomacy.
Related Articles
Pharmalittle: We’re reading about Prasad’s return to FDA, a journal sparring with RFK Jr., and more
Plus more pharma news from the Pharmalittle newsletter.
Pharmalittle: We’re reading about Prasad’s return to FDA, a journal sparring with RFK Jr., and more
Plus more pharma news from the Pharmalittle newsletter.
In internal call, CDC employees recount shooting, ask about RFK Jr.’s response
After a gunman shot up CDC headquarters, employees had harrowing stories and questions about “disinformation that caused this issue.”
If Americans want abundant primary care, health care needs a YIMBY moment
The most cumbersome administrative obstacles that new primary care practices face have little to do with federal regulation.
Inside the research machine that helps UnitedHealth protect its Medicare profits
A STAT Investigation: Inside the research machine that helps UnitedHealth protect its Medicare profits.
I just packed Narcan for my daughter’s dorm room. Public health made it possible
Narcan didn’t just magically show up on pharmacy shelves. It exists because people made it happen.
NASA and Google built a health AI tool for astronauts
In STAT’s Health Tech newsletter: Linda Yaccarino’s new job, UnitedHealth data breaches, and NASA’s health AI.
In internal call, CDC employees recount shooting, ask about RFK Jr.’s response
After a gunman shot up CDC headquarters, employees had harrowing stories and questions about “disinformation that caused this issue.”
Dewpoint Therapeutics, biotech startup in a once-buzzy field, cuts 70% of staff
Dewpoint Therapeutics, a startup working in the once-buzzy field of biomolecular condensates, has laid off most of its staff.
Work on mRNA therapies was surging. Now Kennedy has rocked the field
Companies in a burgeoning field of mRNA therapeutics express shock at HHS’s deep cuts to research funding.